As we reported in our Medical Technology: Year In Review 2017, the medical device space has attracted considerable investment from both strategic acquirers and private equity and venture capital firms over the past year – and as we head into 2018, that brisk pace shows no sign of slowing down.
During Boston Scientific’s 4Q:17 earnings call, where the company reported sales that beat estimates as well as in-line EPS, CEO Mike Mahoney was asked whether M&A would continue to be a priority for the company in the next year. In addition to answering in the affirmative and discussing their current venture portfolio, he noted that the company would have approximately $500 million available to put toward strategic uses in the second half of the year.
We’ve summarized Boston Scientific’s recent M&A and private placement history below, which displays a mix of innovative technologies and their emphasis on the cardiac space:
|Boston Scientific’s LTM Investment History
|| Developing a transcatheter, semi-rigid, complete annuloplasty ring for the treatment of mitral and tricuspid regurgitation.
||Apama Medical, Inc.
||Developing novel catheter ablation technology for atrial fibrillation.
||SetPoint Medical Corporation
||Developing implantable bioelectronic devices to treat inflammatory diseases.
||Channel Medsystems, Inc.
||Developing cryoablation delivery technologies for endometrial ablation.
||Neuros Medical, Inc.
||Developing a neuromodulation technology for chronic pain.
||Amphora Medical, Inc.
||Developing a cystoscopic technology for the treatment of overactive bladder.
||Develops and markets minimally-invasive transcatheter aortic valve implantation (TAVI) devices.
||Corindus Vascular Robotics, Inc.
||Markets a system that enables remote delivery and manipulation of coronary guidewires and balloon/stent catheters during percutaneous coronary and vascular interventional procedures.
We’ll be watching closely as their strategic efforts develop.